🍽️ pimethixene maleate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Anxiety Disorders: Pimethixene maleate is occasionally used off-label as an adjunctive treatment for anxiety disorders. Its sedative properties can help alleviate symptoms of anxiety and promote relaxation. However, it is not typically considered a first-line treatment for anxiety disorders due to the availability of other medications with more established efficacy and safety profiles.

  2. Insomnia: Pimethixene maleate's sedative effects make it useful in the management of insomnia, particularly in cases where sleep disturbances are secondary to anxiety or other conditions. It can help induce sleep and improve sleep continuity, leading to better overall sleep quality.

  3. Allergic Reactions: As an antihistamine, pimethixene maleate can be used to alleviate symptoms associated with allergic reactions, such as itching, hives, and allergic rhinitis. Its antihistaminic properties help block the action of histamine, a chemical involved in allergic responses, thereby reducing symptoms of allergy.

  4. Nausea and Vomiting: Pimethixene maleate's antiemetic properties may make it useful in managing nausea and vomiting, particularly in cases where these symptoms are related to motion sickness, vertigo, or medication side effects. Its ability to block certain neurotransmitter receptors in the brain can help alleviate nausea and suppress the vomiting reflex.

  5. Preoperative Anxiety: Pimethixene maleate is sometimes used as a preoperative medication to reduce anxiety and induce sedation in patients undergoing surgical procedures. By promoting relaxation and sedation, it can help alleviate preoperative apprehension and facilitate a smoother induction of anesthesia.

  6. Side Effects: Common side effects associated with pimethixene maleate include drowsiness, sedation, dizziness, blurred vision, dry mouth, constipation, urinary retention, and cognitive impairment. These side effects are typical of medications with sedative and anticholinergic properties and may vary in intensity depending on individual sensitivity and dosage.

  7. Contraindications: Pimethixene maleate is contraindicated in individuals with known hypersensitivity to the drug or its components, as well as in individuals with narrow-angle glaucoma, urinary retention, severe liver impairment, or certain cardiovascular conditions. It should be used with caution in the elderly and in individuals with respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD).

  8. Drug Interactions: Pimethixene maleate may interact with other medications that have sedative or CNS depressant effects, including alcohol, benzodiazepines, opioids, and certain antidepressants. Concurrent use of these medications may potentiate sedation and increase the risk of adverse effects.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of pimethixene maleate,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by pimethixene maleate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Phocaeicola genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Lachnospira genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Clostridioides genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Enterocloster genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Odoribacter splanchnicus species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Bacteroides ovatus species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Agathobacter rectalis species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Enterocloster bolteae species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of pimethixene maleate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.3 -0.3
ADHD 5.4 0.1 53
Age-Related Macular Degeneration and Glaucoma 0.5 0.5 0
Allergic Rhinitis (Hay Fever) 1.2 1.6 -0.33
Allergies 5.1 3 0.7
Allergy to milk products 1 0.9 0.11
Alopecia (Hair Loss) 2.2 2.2
Alzheimer's disease 3.8 5.3 -0.39
Amyotrophic lateral sclerosis (ALS) Motor Neuron 4.4 1.2 2.67
Ankylosing spondylitis 3.8 1.2 2.17
Anorexia Nervosa 0.5 2.5 -4
Antiphospholipid syndrome (APS) 1.1 1.1
Asthma 0.7 1.9 -1.71
Atherosclerosis 1.1 1.8 -0.64
Atrial fibrillation 3.6 2.1 0.71
Autism 8.3 10.7 -0.29
Barrett esophagus cancer 0.4 0.4
benign prostatic hyperplasia 0 0
Bipolar Disorder 1.3 1 0.3
Brain Trauma 0.8 0.7 0.14
Cancer (General) 0.5 2.7 -4.4
Carcinoma 3.4 3.3 0.03
Celiac Disease 2.4 4.8 -1
Cerebral Palsy 1.3 1.4 -0.08
Chronic Fatigue Syndrome 5.2 7.7 -0.48
Chronic Kidney Disease 1.1 1.9 -0.73
Chronic Lyme 0.7 -0.7
Chronic Obstructive Pulmonary Disease (COPD) 0.4 0.7 -0.75
Chronic Urticaria (Hives) 0.6 2.6 -3.33
Coagulation / Micro clot triggering bacteria 0.6 1 -0.67
Colorectal Cancer 3.3 1.1 2
Constipation 2 0.7 1.86
Coronary artery disease 1.1 0.8 0.38
COVID-19 11.9 15.2 -0.28
Crohn's Disease 6.6 7.1 -0.08
cystic fibrosis 0.1 1 -9
deep vein thrombosis 0.1 0.5 -4
Depression 9.6 8.2 0.17
Dermatomyositis 0.3 -0.3
Eczema 0.4 1.5 -2.75
Endometriosis 2.2 1.6 0.38
Eosinophilic Esophagitis 0.4 -0.4
Epilepsy 3.1 4 -0.29
Fibromyalgia 2.7 2.8 -0.04
Functional constipation / chronic idiopathic constipation 5.8 3.8 0.53
gallstone disease (gsd) 2.1 0.5 3.2
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 2.3 0.9 1.56
Generalized anxiety disorder 0.5 1.6 -2.2
giant cell arteritis 0.2 -0.2
Graves' disease 1.7 1.4 0.21
Halitosis 0.8 0.8
Hashimoto's thyroiditis 2.2 0.8 1.75
Hidradenitis Suppurativa 0.4 -0.4
hypercholesterolemia (High Cholesterol) 0.7 0.8 -0.14
hyperglycemia 0 3 0
Hyperlipidemia (High Blood Fats) 1.2 0.4 2
hypersomnia 0.5 -0.5
hypertension (High Blood Pressure 2.5 4.8 -0.92
Hypothyroidism 0.9 -0.9
Hypoxia 1.4 1.4
IgA nephropathy (IgAN) 5.2 -5.2
Inflammatory Bowel Disease 2.4 9.7 -3.04
Insomnia 0.9 1.2 -0.33
Intelligence 1.2 0.8 0.5
Intracranial aneurysms 1.7 0.4 3.25
Irritable Bowel Syndrome 4.6 6.1 -0.33
Liver Cirrhosis 4 2.6 0.54
Long COVID 7.5 10.1 -0.35
Low bone mineral density 0.7 -0.7
Lung Cancer 0.9 1.9 -1.11
Mast Cell Issues / mastitis 0 0.6 0
ME/CFS with IBS 0.4 2.4 -5
ME/CFS without IBS 0.6 2.7 -3.5
Menopause 2.2 2.2
Metabolic Syndrome 7 9.4 -0.34
Mood Disorders 12.2 8.3 0.47
multiple chemical sensitivity [MCS] 0.8 0.5 0.6
Multiple Sclerosis 4.1 6.5 -0.59
Multiple system atrophy (MSA) 1.7 1.1 0.55
neuropathic pain 2 -2
Neuropathy (all types) 0.9 0 0
neuropsychiatric disorders (PANDAS, PANS) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.2 6.3 -1.86
NonCeliac Gluten Sensitivity 0.3 -0.3
Obesity 7.4 4.5 0.64
obsessive-compulsive disorder 8.1 4.1 0.98
Osteoarthritis 0.7 0.3 1.33
Osteoporosis 1.4 1.8 -0.29
pancreatic cancer 0.5 0.5
Parkinson's Disease 2.7 3.2 -0.19
Polycystic ovary syndrome 2.9 2.2 0.32
Postural orthostatic tachycardia syndrome 0.2 0.3 -0.5
Premenstrual dysphoric disorder 1.2 0.5 1.4
primary biliary cholangitis 0.3 1.4 -3.67
Psoriasis 4.6 3.8 0.21
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 5.8 3.8 0.53
Rosacea 0.6 0.4 0.5
Schizophrenia 7.5 1.5 4
scoliosis 1.3 -1.3
Sjögren syndrome 3.3 4.1 -0.24
Sleep Apnea 1.1 1.2 -0.09
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.7 -6
Stress / posttraumatic stress disorder 2.5 2.5 0
Systemic Lupus Erythematosus 3.4 2.3 0.48
Tic Disorder 1.8 1.9 -0.06
Tourette syndrome 0.4 0.5 -0.25
Type 1 Diabetes 4.4 2.5 0.76
Type 2 Diabetes 7.8 8.3 -0.06
Ulcerative colitis 1.8 7.1 -2.94
Unhealthy Ageing 4 2.2 0.82

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.222.64 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.64 ]